Table 1 Clinicopathological characteristics of patients and samples according to the molecular subtype.
Characteristics | N | ER+ Luminal | ER+ Basal | p valuea | N | ER− Basal | p valueb |
|---|---|---|---|---|---|---|---|
Patients’ age | 0.296 | 7.89E−26 | |||||
≤50 years | 1335 | 1115 (33%) | 220 (31%) | 632 | 632 (49%) | ||
>50 years | 2795 | 2296 (67%) | 499 (69%) | 666 | 666 (51%) | ||
Pathological type | 0.561 | 3.48E−16 | |||||
Ductal | 2241 | 1825 (74%) | 416 (76%) | 710 | 710 (85%) | ||
Lobular | 394 | 324 (13%) | 70 (13%) | 21 | 21 (3%) | ||
Other | 380 | 318 (13%) | 62 (11%) | 103 | 103 (12%) | ||
Pathological grade | 7.91E−22 | 1.86E−251 | |||||
1 | 637 | 562 (18%) | 75 (11%) | 15 | 15 (1%) | ||
2 | 1941 | 1660 (54%) | 281 (42%) | 160 | 160 (14%) | ||
3 | 1137 | 829 (27%) | 308 (46%) | 997 | 997 (85%) | ||
Pathological tumor size (pT) | 3.25E−03 | 3.38E−10 | |||||
pT1 | 1431 | 1207 (42%) | 224 (38%) | 288 | 288 (31%) | ||
pT2 | 1681 | 1398 (49%) | 283 (49%) | 542 | 542 (57%) | ||
pT3 | 324 | 248 (9%) | 76 (13%) | 114 | 114 (12%) | ||
Pathological axillary lymph node status (pN) | 0.275 | 0.38 | |||||
Negative | 2168 | 1791 (58%) | 377 (55%) | 596 | 596 (59%) | ||
Positive | 1626 | 1320 (42%) | 306 (45%) | 422 | 422 (41%) | ||
TP53 mutation status | 2.77E−12 | 6.02E−42 | |||||
Wild-type | 1559 | 1323 (95%) | 236 (84%) | 255 | 255 (71%) | ||
Mutated | 108 | 63 (5%) | 45 (16%) | 103 | 103 (29%) | ||
Mammaprint relapse risk | 3.94E−56 | 1.99E−231 | |||||
Low | 1879 | 1757 (40%) | 122 (13%) | 13 | 13 (1%) | ||
High | 3393 | 2584 (60%) | 809 (87%) | 1647 | 1647 (99%) | ||
Recurrent score relapse risk | 2.43E−121 | <2.00E−255 | |||||
Low | 2110 | 1968 (45%) | 142 (15%) | 19 | 19 (1%) | ||
Intermediate | 1575 | 1357 (31%) | 218 (23%) | 1555 | 86 (5%) | ||
High | 1587 | 1016 (23%) | 571 (61%) | 86 | 1555 (94%) | ||
EndoPredict relapse risk | 3.15E−73 | <2.00E−255 | |||||
Low | 2729 | 2498 (58%) | 231 (25%) | 19 | 19 (1%) | ||
High | 2543 | 1843 (42%) | 700 (75%) | 1641 | 1641 (99%) | ||
Pathological complete response (pCR) | 3.72E−08 | 1.08E−15 | |||||
No | 468 | 410 (91%) | 58 (68%) | 271 | 271 (69%) | ||
Yes | 69 | 42 (9%) | 27 (32%) | 123 | 123 (31%) | ||
Adjuvant HT | 0.369 | 3.25E−83 | |||||
No | 1375 | 1134 (47%) | 241 (49%) | 655 | 655 (87%) | ||
Yes | 1542 | 1292 (53%) | 250 (51%) | 101 | 101 (13%) | ||
Adjuvant CT | 0.129 | 1.96E−45 | |||||
No | 3097 | 2598 (87%) | 499 (84%) | 756 | 756 (67%) | ||
Yes | 496 | 402 (13%) | 94 (16%) | 367 | 367 (33%) | ||
5-year DRFI, % (95% CI) | 2008 | 79% (77−82) | 81% (77−86) | 0.24 | 630 | 62% (58−67) | 1.11E−15 |
DRFI event, yes | 2008 | 362 (22%) | 63 (18%) | 0.168 | 630 | 201 (32%) | 1.60E−07 |
